Inhibitory Effect of Multimodal Nanoassemblies against Glycative and Oxidative Stress in Cancer and Glycation Animal Models

Figure 5

(a) Lowering of the CML content in the presence of PFT-HSA-TFT-Cy7 and PFT-Hcy-HSA-Cy7 in the lung cancer animal model. (b) Lowering of the CML content in the presence of PFT-HSA-TFT-Cy7 and PFT-Hcy-HSA-Cy7 in the glycation animal model. (c) Lowering of the CML content in the presence of PFT-HSA-TFT-Cy7 and PFT-Hcy-HSA-Cy7 and in the in vitro model system.

(a)

(b)

(c)